BVS Stock: Price, Earnings History and SEC Filings
Bioventus Inc. (BVS) last traded at $13.33, down 10.39% on the latest session and down 2.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.22 against an analyst estimate of $0.22, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BVS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.22 | $0.22 | +0.00% |
| Mar 2026 | May 6, 2026 | $0.15 | $0.09 | +66.67% |
| Dec 2025 | Mar 5, 2026 | $0.24 | $0.22 | +9.09% |
BVS beat the analyst EPS estimate in 2 of its last 3 reported quarters. Source: Nasdaq.
How BVS reacts to earnings
Across its last 8 earnings releases, BVS moved 13.6% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +13.71% |
| 2026-05-06 | Before open | +2.25% |
| 2026-03-05 | Before open | +7.44% |
| 2025-11-04 | Before open | +15.09% |
| 2025-08-06 | Before open | +18.73% |
| 2025-05-06 | Before open | -11.81% |
| 2025-03-11 | Before open | +23.29% |
| 2024-11-05 | Before open | -16.27% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BVS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $568M | $23M | $72M | 4.0% | $0.33 |
| 2024 | $573M | -$36M | $38M | -6.3% | $-0.56 |
| 2023 | $512M | -$156M | $8M | -30.5% | $-2.49 |
| 2022 | $512M | -$159M | -$15M | -31.0% | $-2.59 |
| 2021 | $431M | $19M | $9M | 4.5% | $-0.15 |
| 2020 | $321M | $16M | $55M | 5.1% | – |
| 2019 | $340M | $7M | $38M | 2.0% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BVS
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Other events, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote
- 8-K · May 21, 2026Regulation FD disclosure
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 22, 2026
- 10-K · Mar 5, 2026
- 8-K · Mar 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Nov 17, 2025Officer or director change
Insider filing activity
BVS insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BVS news
- Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026Oct 27, 2026 · finance.yahoo.com
About Bioventus Inc.
Bioventus Inc. (BVS) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.